AU2020298031B2 - Succinate prodrug, compositions containing the succinate prodrug and uses thereof - Google Patents

Succinate prodrug, compositions containing the succinate prodrug and uses thereof

Info

Publication number
AU2020298031B2
AU2020298031B2 AU2020298031A AU2020298031A AU2020298031B2 AU 2020298031 B2 AU2020298031 B2 AU 2020298031B2 AU 2020298031 A AU2020298031 A AU 2020298031A AU 2020298031 A AU2020298031 A AU 2020298031A AU 2020298031 B2 AU2020298031 B2 AU 2020298031B2
Authority
AU
Australia
Prior art keywords
compound
mitochondrial
isolated compound
complex
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020298031A
Other languages
English (en)
Other versions
AU2020298031A1 (en
Inventor
Mats Eskil ELMÉR
Mark Richard FARMERY
Matthew Alan Gregory
Alvar GRÖNBERG
Magnus Joakim HANSSON
Steven James Moss
Lee Robert WEBSTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abliva AB
Original Assignee
Abliva AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abliva AB filed Critical Abliva AB
Publication of AU2020298031A1 publication Critical patent/AU2020298031A1/en
Application granted granted Critical
Publication of AU2020298031B2 publication Critical patent/AU2020298031B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/30—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2020298031A 2019-06-19 2020-06-18 Succinate prodrug, compositions containing the succinate prodrug and uses thereof Active AU2020298031B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA201970383 2019-06-19
DKPA201970382 2019-06-19
DKPA201970384 2019-06-19
DKPA201970384 2019-06-19
DKPA201970382 2019-06-19
DKPA201970383 2019-06-19
PCT/EP2020/066923 WO2020254484A1 (en) 2019-06-19 2020-06-18 Succinate prodrug, compositions containing the succinate prodrug and uses thereof

Publications (2)

Publication Number Publication Date
AU2020298031A1 AU2020298031A1 (en) 2022-02-03
AU2020298031B2 true AU2020298031B2 (en) 2025-12-18

Family

ID=71130953

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020298031A Active AU2020298031B2 (en) 2019-06-19 2020-06-18 Succinate prodrug, compositions containing the succinate prodrug and uses thereof

Country Status (11)

Country Link
US (2) US11565998B2 (enExample)
EP (2) EP4360708A3 (enExample)
JP (2) JP7699551B2 (enExample)
KR (1) KR102871719B1 (enExample)
CN (1) CN113993842B (enExample)
AU (1) AU2020298031B2 (enExample)
CA (1) CA3143112A1 (enExample)
IL (1) IL288990B2 (enExample)
MA (1) MA56506A (enExample)
MX (1) MX2021015137A (enExample)
WO (1) WO2020254484A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL288990B2 (en) * 2019-06-19 2025-09-01 Abliva Ab Succinate drug meters, preparations containing the succinate drug meters and its uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612331D0 (en) 1996-06-13 1996-08-14 Leo Pharm Prod Ltd Chemical compounds
AUPR059400A0 (en) 2000-10-06 2000-11-02 Bar-Ilan University Formaldehyde-releasing prodrugs
CN106255509A (zh) * 2014-04-08 2016-12-21 纽维制药有限公司 用于在归因于线粒体氧化磷酸化的复合体i相关损伤的乳酸性酸中毒或药物诱导的副作用的治疗中应用的琥珀酸酯前药
CN106458957B (zh) * 2014-04-08 2020-08-18 爱博利瓦有限公司 新型细胞可渗透琥珀酸化合物
IL288990B2 (en) * 2019-06-19 2025-09-01 Abliva Ab Succinate drug meters, preparations containing the succinate drug meters and its uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S. MURLI, ET AL, APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 71, no. 8, 5 August 2005 (2005-08-05), American Society for Microbiology, Washington, DC, US, pages 4503 - 4509 *

Also Published As

Publication number Publication date
US11565998B2 (en) 2023-01-31
US20220162162A1 (en) 2022-05-26
MX2021015137A (es) 2022-01-18
IL288990B2 (en) 2025-09-01
JP2025004155A (ja) 2025-01-14
EP4360708A2 (en) 2024-05-01
EP4360708A3 (en) 2024-12-25
KR102871719B1 (ko) 2025-10-15
JP2022538009A (ja) 2022-08-31
CN113993842A (zh) 2022-01-28
EP3986862B1 (en) 2024-01-24
KR20220024780A (ko) 2022-03-03
US20230033294A1 (en) 2023-02-02
US12162824B2 (en) 2024-12-10
EP3986862A1 (en) 2022-04-27
EP3986862C0 (en) 2024-01-24
CA3143112A1 (en) 2020-12-24
IL288990A (en) 2022-02-01
CN113993842B (zh) 2024-07-16
WO2020254484A1 (en) 2020-12-24
JP7699551B2 (ja) 2025-06-27
BR112021024510A2 (pt) 2022-01-18
AU2020298031A1 (en) 2022-02-03
IL288990B1 (en) 2025-05-01
MA56506A (fr) 2022-04-27

Similar Documents

Publication Publication Date Title
KR102322543B1 (ko) 신규한 세포-투과성 숙신산 화합물
TW201117826A (en) Fatty acid niacin conjugates and their uses
MXPA01008549A (es) Metodos de tratamiento de desordenes mitocondriales.
JP2016538281A (ja) 血液脳関門を通過するタンパク質ホスファターゼ阻害剤
JP6010196B2 (ja) オキサゾリジノン含有二量体化合物、組成物、ならびに作製および使用方法
US20240299364A1 (en) Magnesium biotinate compositions and methods of use
EP4244221B1 (en) Prodrug of pyrrolidone derivatives as glucokinase activator
US12162824B2 (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
KR20210070978A (ko) 화합물 및 이의 용도
WO2010074591A1 (ru) Амиды креатина, способ их получения, средство, обладающее нейропротекторным действием
US11999708B1 (en) Thiazole tethered organoselenides as 5-lipoxygenase inhibitors
HK40110815A (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
WO2017060400A1 (en) Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
HK40072910A (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
HK40072910B (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
BR112021024510B1 (pt) 3-[(2-acetilaminoetiltio)carbonil]propionato de metila isolado, cosmecêutico, nutricosméticos, bebida energética, e, composição farmacêutica
US20130209366A1 (en) Glutathione-Lanthionine Compounds and Methods Related Thereto
RU2354645C1 (ru) Амиды креатина, способ их получения, средство, обладающее нейропротекторным действием
US11504355B2 (en) Ergothioneine compositions and methods for maintaining and/or increasing vitamin C levels in cells and organisms
EA045539B1 (ru) Сукцинатное пролекарство, композиции, содержащие сукцинатное пролекарство, и их применение
WO2017060418A1 (en) Protected carboxylic acid-based metabolites for the treatment of mitochondria-related diseases
US11958857B1 (en) 5-(1H-indol-3-yl)-1,3-substitutedpyrimido[4,5-d]pyrimidine-2,4,7(1H,3H,8H)-trione as anticancer agents
CN106146612B (zh) 一类乙二醛酶i不可逆抑制剂及其制备方法和用途
US10058618B2 (en) PAK1-blocking 1,2,3-triazolyl esters
WO2024026200A1 (en) Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome